HUTCHMED (LON:HCM) Hits New 12-Month Low – Here’s Why

HUTCHMED (China) Limited (LON:HCM) shares reached a new 52-week low during trading on Thursday . The stock traded as low as GBX 154 and last traded at GBX 156.97, with a volume of 6823 shares. The stock had previously closed at GBX 157.50.

HUTCHMED Price Performance

The firm has a market capitalization of £1.35 billion, a PE ratio of 2.96 and a beta of 0.45. The company has a debt-to-equity ratio of 7.91, a quick ratio of 2.97 and a current ratio of 4.96. The business’s 50 day moving average is GBX 189.77 and its two-hundred day moving average is GBX 204.99.

HUTCHMED Company Profile

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).